Catatonia

Summary

Catatonia (MONDO:0800105) is a disease and 14 clinical trials. Top therapeutic interventions include clonidine, clonazepam, and lorazepam. A subtype of psychiatric disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	catatonia
Mondo ID	MONDO:0800105
MeSH	D002389
ICD-11	486722075
UMLS	C0007398
MedGen	2904
Is cancer (heuristic)	no

Disease family

This is a subtype of psychiatric disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › catatonia

Related subtypes (13): sexual disorder, dissociative disorder, impulse control disorder, personality disorder, cognitive disorder, factitious disorder, substance-related disorder, somatoform disorder, mental disorder, eating disorder, enuresis, Alice in Wonderland syndrome, body integrity dysphoria

Subtypes (1): idiopathic catatonia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	11
PHASE1	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04828226	PHASE4	COMPLETED	Clonidine to Prevent Delirium After Electroconvulsive Therapy.
NCT02462109	PHASE1	COMPLETED	Catatonia in Nodding Syndrome and Lorazepam Treatment
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT04530734	Not specified	RECRUITING	Blood Concentration in Lorazepam and Treatment in Adult Catatonia
NCT06656572	Not specified	NOT_YET_RECRUITING	Immunogenomic Analyses of Pediatric Catatonia
NCT07315386	Not specified	RECRUITING	Catatonic Syndrome in Adult Patients at Basurto Hospital: A Descriptive Study of Incidence, Comorbidity, and Short-Term Outcomes
NCT07498387	Not specified	ACTIVE_NOT_RECRUITING	Management of Catatonic Features in Adolescents With Profound Autism
NCT07561307	Not specified	NOT_YET_RECRUITING	Optimizing Stimulation Parameters for Electroconvulsive Therapy
NCT02734498	Not specified	TERMINATED	Prospective Treatment Study of Catatonia Patients
NCT02868879	Not specified	COMPLETED	Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
NCT02945423	Not specified	WITHDRAWN	Improving the Understanding of Catatonia in Autism
NCT04335916	Not specified	UNKNOWN	Survey on Pre-ECT Evaluation and ECT Application
NCT06139432	Not specified	UNKNOWN	Catatonia: Effectiveness of Transcranial Direct Current Electrostimulation (CATATOES)
NCT06176456	Not specified	UNKNOWN	Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLONIDINE	4	2
CLONAZEPAM	4	1
LORAZEPAM	4	1